EUVIMEDSkopri EUVIMED
Open access · CC BY-NC 4.0

Targeting the noncatalytic activity of GSK3β modulates neuronal excitability in medium spiny neurons via Nav1.6 interactions

Aditya K Singh, Zahra Haghighijoo, Akanksha Gurtu, Nolan M Dvorak, Timothy J Baumgartner, Nana A Goode, Jully Singh, Matteo Bernabucci, Adam T Szafran, Michael J Bolt, Michael A Mancini, Natalie M Dvorak and 8 more

British Journal of Pharmacology · 2026-08 · 183 (15) · 4344-4363

DOI: 10.1111/bph.70458 ↗

At a glance

Journal article in British Journal of Pharmacology, published online on 2026-04-28. Written by Aditya K Singh and 19 co-authors. Institution: Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas, USA. Major MEDLINE topics: NAV1.6 Voltage-Gated Sodium Channel, Glycogen Synthase Kinase 3 beta, Medium Spiny Neurons, Neurons. Cited 1 times so far (Crossref); 57 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: NIMH NIH HHS, NIH HHS, NIGMS NIH HHS.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background and Purpose Kinases phosphorylate ion channels, but their noncatalytic roles via protein–protein interactions (PPI) are less understood. Here, we identified the peptidomimetic ZL141 to characterize the PPI between GSK3β and Nav1.6, revealing a noncatalytic role for GSK3β in regulating Nav1.6 currents and neuronal excitability. Experimental Approach To screen peptide inhibitors, the GSK3β/Nav1.6 C‐terminal tail (CTD) PPI was reconstituted using split‐luciferase complementation assay. Intrinsic fluorescence spectroscopy (IFS), surface plasmon resonance (SPR), kinase assays, and molecular docking were used to assess peptidomimetic binding and predict the PPI interface. ZL141's function was evaluated via patch‐clamp electrophysiology in heterologous cells and nucleus accumbens (NAc) medium spiny neurons (MSNs), along with in vivo GSK3β silencing. Key Results ZL141 disrupts GSK3β/Nav1.6 CTD complex formation without altering GSK3β's catalytic activity. AlphaFold modelling predicted the ZL141 binding site at the surface of the GSK3β/Nav1.6 CTD PPI interface. ZL141 has a micromolar affinity for GSK3β, suppresses Na + currents, and affects Nav1.6 activation and inactivation kinetics. In vivo, silencing GSK3β in the NAc mimics the inhibitory effects of ZL141 on MSN firing and occludes any further pharmacological activity of the compound. Conclusions and Implications These findings reveal a critical PPI role of GSK3β in transducing Nav1.6 function and contributing to MSN firing. Both GSK3β and Nav1.6 activities are dysregulated in neurological and neuropsychiatric disorders. Given that Nav1.6 hyperactivity is implicated in maladaptive reward signalling, PPI‐targeted modulation using compounds like ZL141 may offer a precision pharmacological strategy for treating psychiatric disorders such as bipolar disorder or schizophrenia.

Subjects

MeSH terms (MEDLINE)

NAV1.6 Voltage-Gated Sodium ChannelGlycogen Synthase Kinase 3 betaMedium Spiny NeuronsNeuronsAnimalsHumansHEK293 CellsMolecular Docking SimulationMaleMiceProtein BindingRats

Author keywords

glycogen synthase kinase 3β (GSK3β)in vivo gene silencingmedium spiny neurons (MSNs)protein–protein interactions (PPI)split‐luciferase complementation assay (LCA)voltage‐gated Na+ channel Nav1.6

Substances

NAV1.6 Voltage-Gated Sodium ChannelGlycogen Synthase Kinase 3 beta

Authors and institutions

  • Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas, USA.
  • IonTX Inc, Friendswood, Texas, USA.
  • Department of Molecular Biology, Baylor College of Medicine, Houston, Texas, USA.
  • Advanced Technology Cores, Baylor College of Medicine, Houston, Texas, USA.
  • GCC Center for 5 Advanced Microscopy and Image Informatics, Houston, Texas, USA.
  • Department of Biostatistics and Data Science, University of Texas Medical Branch, Galveston, Texas, USA.

Funding

  • NIMH NIH HHS
  • NIH HHS
  • NIGMS NIH HHS
  • Cancer Prevention and Research Institute of Texas (CPRIT)
  • Integrated Microscopy Core at Baylor College of Medicine
  • NIEHS NIH HHS
  • UTMB Technology Commercialization Program
  • John S. Dunn Gulf Coast Consortium for Chemical Genomics

Cite

APA

Singh, A. K., Haghighijoo, Z., Gurtu, A., Dvorak, N. M., Baumgartner, T. J., Goode, N. A., Singh, J., Bernabucci, M., Szafran, A. T., Bolt, M. J., Mancini, M. A., Dvorak, N. M., Lijffijt, M., Liu, Z., Xue, Y., Thomas, A. K., Villasante-Tezanos, A., Krishnan, B., Zhou, J., & Laezza, F. (2026). Targeting the noncatalytic activity of GSK3β modulates neuronal excitability in medium spiny neurons via Nav1.6 interactions. British Journal of Pharmacology, 183(15), 4344-4363. https://doi.org/10.1111/bph.70458

Vancouver

Singh AK, Haghighijoo Z, Gurtu A, Dvorak NM, Baumgartner TJ, Goode NA, et al. Targeting the noncatalytic activity of GSK3β modulates neuronal excitability in medium spiny neurons via Nav1.6 interactions. British Journal of Pharmacology. 2026;183(15):4344-4363. doi:10.1111/bph.70458

BibTeX
@article{Singh2026,
  author = {Singh, Aditya K and Haghighijoo, Zahra and Gurtu, Akanksha and Dvorak, Nolan M and Baumgartner, Timothy J and Goode, Nana A and Singh, Jully and Bernabucci, Matteo and Szafran, Adam T and Bolt, Michael J and Mancini, Michael A and Dvorak, Natalie M and Lijffijt, Marijn and Liu, Zhiqing and Xue, Yu and Thomas, Alyssa K and Villasante-Tezanos, Alejandro and Krishnan, Balaji and Zhou, Jia and Laezza, Fernanda},
  title = {Targeting the noncatalytic activity of GSK3β modulates neuronal excitability in medium spiny neurons via Nav1.6 interactions},
  journal = {British Journal of Pharmacology},
  year = {2026},
  volume = {183},
  number = {15},
  pages = {4344--4363},
  doi = {10.1111/bph.70458}
}
Start for free →